<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02343458</url>
  </required_header>
  <id_info>
    <org_study_id>PT003014</org_study_id>
    <nct_id>NCT02343458</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD</brief_title>
  <official_title>A Randomized, Double-Blind, Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A chronic dosing (24 weeks) study to assess the efficacy and safety GFF MDI; PT003), FF MDI;
      PT005, and GP MDI; PT001) in subjects with moderate to very severe COPD, compared with
      placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, chronic dosing (24 weeks), placebo-controlled, parallel group,
      multi-center study to assess the efficacy and safety of glycopyrronium and formoterol
      fumarate inhalation aerosol (GFF; PT003), formoterol fumarate inhalation aerosol (FF; PT005),
      and glycopyrronium inhalation aerosol (GP; PT001) in subjects with moderate to very severe
      COPD, compared with placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 30, 2015</start_date>
  <completion_date type="Actual">August 31, 2017</completion_date>
  <primary_completion_date type="Actual">August 31, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 of Treatment (US/China Approach)</measure>
    <time_frame>at week 24</time_frame>
    <description>For the US/China approach, the primary endpoint was the change from baseline in morning pre-dose trough FEV1 at Week 24 of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Morning Pre-dose Trough FEV1 Over Weeks 12-24, Japan Approach</measure>
    <time_frame>over weeks 12-24</time_frame>
    <description>Change from baseline in morning pre-dose trough FEV1 over weeks 12-24, Japan approach</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks. Primary Endpoint, EU/SK/TW Approach, Secondary Endpoint US/China Approach.</measure>
    <time_frame>over 24 weeks</time_frame>
    <description>Change from baseline in morning pre-dose trough FEV1 over 24 weeks. Primary endpoint, EU/SK/TW approach, Secondary endpoint US/China approach.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TDI Focal Score Over 24 Weeks, US/China and EU/SK/TW Approach</measure>
    <time_frame>over 24 Weeks</time_frame>
    <description>TDI focal score over 24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TDI Focal Score Over Weeks 12-24 Japan Approach</measure>
    <time_frame>over Weeks 12-24</time_frame>
    <description>TDI focal score over 12-24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TDI Focal Score Over 24 Weeks - US/China and EU/SK/TW Approaches -Symptomatic Population</measure>
    <time_frame>over 24 Weeks</time_frame>
    <description>TDI focal score over 24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TDI Focal Score Over Weeks 12-24 - Japan Approach - Symptomatic Population</measure>
    <time_frame>over weeks 12-24</time_frame>
    <description>TDI focal score over 12-24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing at Week 24 US/China Approach</measure>
    <time_frame>at week 24</time_frame>
    <description>Peak change from baseline in FEV1 within 2 hours post-dosing at Week 24 US/China approach</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over Weeks 12-24 Japan Approach</measure>
    <time_frame>over weeks 12-24</time_frame>
    <description>Peak change from baseline in FEV1 within 2 hours post-dosing over weeks 12-24 Japan approach</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over 24 Weeks EU/SK/TW Approach</measure>
    <time_frame>over 24 weeks</time_frame>
    <description>Peak change from baseline in FEV1 within 2 hours post-dosing over 24 weeks EU/SK/TW approach</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SGRQ Total Score at Week 24, US/China Approach</measure>
    <time_frame>at week 24</time_frame>
    <description>Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SGRQ Total Score Over Weeks 12-24 , Japan &amp; EU/SK/TW Approach</measure>
    <time_frame>over weeks 12-24</time_frame>
    <description>Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SGRQ Total Score at Week 24 in Symptomatic Population, US/China Approach</measure>
    <time_frame>at week 24</time_frame>
    <description>Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SGRQ Total Score Over Weeks 12-24, in Symptomatic Population, Japan &amp; EU/SK/TW Approach</measure>
    <time_frame>over weeks 12-24</time_frame>
    <description>Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Daily Rescue Ventolin Use Over 24 Weeks in RVU Population, All Approaches</measure>
    <time_frame>over 24 weeks</time_frame>
    <description>Change from baseline in average daily rescue Ventolin use over 24 weeks in RVU population, all approaches</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Measured at 5 Minutes Post-dose on Day 1</measure>
    <time_frame>Assessed at 5-minutes post dose on Day 1</time_frame>
    <description>Onset of Action as Assessed by FEV1 Day 1 at 5 Minutes Post-Dose. Reported is the FEV1 measured at 5 minutes post-dose on Day 1 as the first time point when the difference from Placebo was statistically significant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Measured at 15 Minutes Post-dose on Day 1</measure>
    <time_frame>Assessed at 15-minute post dose on Day 1</time_frame>
    <description>Onset of Action as Assessed by FEV1 Day 1 at 15 Minutes Post-Dose. Reported is the FEV1 measured at 15 minutes post-dose on Day 1 as the first time point when the difference from Placebo was statistically significant</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1756</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>GFF MDI (PT003)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FF MDI (PT005)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GP MDI (PT001)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo MDI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GFF MDI (PT003)</intervention_name>
    <description>Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)</description>
    <arm_group_label>GFF MDI (PT003)</arm_group_label>
    <other_name>Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FF MDI (PT005)</intervention_name>
    <description>Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)</description>
    <arm_group_label>FF MDI (PT005)</arm_group_label>
    <other_name>Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GP MDI (PT001)</intervention_name>
    <description>Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)</description>
    <arm_group_label>GP MDI (PT001)</arm_group_label>
    <other_name>Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo MDI</intervention_name>
    <description>Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)</description>
    <arm_group_label>Placebo MDI</arm_group_label>
    <other_name>Placebo (matching) for GFF MDI, FF MDI, and GP MDI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-child bearing potential (ie, physiologically incapable of becoming pregnant,
             including any female who is 2 years post-menopausal); or Child bearing potential, has
             a negative serum pregnancy test at Visit 1, and agrees to acceptable contraceptive
             methods used consistently and correctly for the duration of the study.

          -  Subjects with an established clinical history of COPD as defined by the American
             Thoracic Society (ATS)/European Respiratory Society (ERS).

          -  Current or former smokers with a history of at least 10 pack-years of cigarette
             smoking.

          -  Forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) ratio of &lt;0.70.

          -  FEV1 must be &lt;80% predicted normal value calculated using the Third National Health
             and Nutrition Examination Survey (NHANES III) reference equations. (Or reference norms
             applicable to other regions).

        Exclusion Criteria:

          -  Significant diseases other than COPD, ie, disease or condition which, in the opinion
             of the Investigator, may put the subject at risk because of participation in the study
             or may influence either the results of the study or the subject's ability to
             participate in the study.

          -  Women who are pregnant or lactating or women of childbearing potential who are not
             using an acceptable method of contraception.

          -  Subjects, who in the opinion of the Investigator, have a current diagnosis of asthma.

          -  Subjects who have been hospitalized due to poorly controlled COPD within 3 months
             prior to Visit 1 (Screening) or during the Screening Period (Visit 1 to Visit 4).

          -  Subjects who have poorly controlled COPD, defined as acute worsening of COPD that
             requires treatment with oral corticosteroids or antibiotics within 6 weeks prior to
             Visit 1 (Screening) or during the Screening Period (Visit 1 to Visit 4).

          -  Subjects with a diagnosis of angle closure glaucoma will be excluded, regardless of
             whether or not they have been treated. Subjects with a diagnosis of open angle
             glaucoma who have intraocular pressure controlled with medication(s) are eligible.

          -  Subjects who have a history of hypersensitivity to β2-agonists, glycopyrronium or
             other muscarinic anticholinergics, or any component of the MDI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Reisner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Pearl Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Andalusia</city>
        <state>Alabama</state>
        <zip>36420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Foley</city>
        <state>Alabama</state>
        <zip>36535</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <zip>35501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789-4681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Blue Ridge</city>
        <state>Georgia</state>
        <zip>30513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Charles</city>
        <state>Missouri</state>
        <zip>63301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <zip>28054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45419</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <zip>29640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <zip>29341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seneca</city>
        <state>South Carolina</state>
        <zip>29678</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <zip>29379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Abingdon</city>
        <state>Virginia</state>
        <zip>24210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100144</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changchun</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changsha</city>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chengdu</city>
        <zip>610083</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chengdu</city>
        <zip>CN-610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guiyang</city>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haikou</city>
        <zip>570311</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hefei</city>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hohhot</city>
        <zip>010017</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanchang</city>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanjing</city>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanning</city>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shengyang</city>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shenyang</city>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shijiazhuang</city>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shijiazhuang</city>
        <zip>050051</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Soochow City</city>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taiyuan</city>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wuxi</city>
        <zip>214023</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xiamen</city>
        <zip>361004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xining</city>
        <zip>810007</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yiyang Shi</city>
        <zip>413000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <zip>37701</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrava-Hrabuvka</city>
        <zip>700 30</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha</city>
        <zip>15000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Teplice</city>
        <zip>415 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Augsburg</city>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10629</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>12157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grosshansdof</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lübeck</city>
        <zip>23552</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65187</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1135</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gödöllő</city>
        <zip>2100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pécs</city>
        <zip>7635</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Siófok</city>
        <zip>8600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szeged</city>
        <zip>H-6722</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ako-shi</city>
        <zip>678-0239</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Asahikawa-shi</city>
        <zip>070-8644</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo-ku</city>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo-ku</city>
        <zip>103-0028</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <zip>811-1394</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamamatsu-shi</city>
        <zip>434-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Himeji-shi</city>
        <zip>671-0102</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Himeji-shi</city>
        <zip>672-8064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hitachinaka-shi</city>
        <zip>312-0057</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Itabashi-ku</city>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kakogawa-shi</city>
        <zip>675-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kamogawa-shi</city>
        <zip>296-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kanazawa-shi</city>
        <zip>920-8201</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kishiwada-shi</city>
        <zip>596-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kobe-shi</city>
        <zip>650-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koga-shi</city>
        <zip>811-3195</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsumoto-shi</city>
        <zip>390-0872</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsumoto-shi</city>
        <zip>390-8621</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mito-shi</city>
        <zip>310-0015</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagaoka-shi</city>
        <zip>940-2085</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya-shi</city>
        <zip>457-0866</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Naka-gun</city>
        <zip>319-1113</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ohota-ku</city>
        <zip>145-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oita-shi</city>
        <zip>870-0951</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saiki-shi</city>
        <zip>876-0813</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <zip>981-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <zip>983-0824</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seto-shi</city>
        <zip>489-8642</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shimotsuga-gun</city>
        <zip>321-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takamatsu-shi</city>
        <zip>760-8538</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toon-shi</city>
        <zip>791-0281</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yanagawa-shi</city>
        <zip>832-0059</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <zip>232-0066</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <zip>241-0811</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daegu</city>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>04551</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>130-709</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>130-872</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wonju-si</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Białystok</city>
        <zip>15-003</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Białystok</city>
        <zip>15-044</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elbląg</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Inowrocław</city>
        <zip>88-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Piekary Śląskie</city>
        <zip>41-94O</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-205</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Skierniewice</city>
        <zip>96-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tarnów</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa Targowek</city>
        <zip>03-291</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Łódź</city>
        <zip>90-203</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gatchina</city>
        <zip>188300</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>105229</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>127018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pytigorsk</city>
        <zip>357538</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>198260</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>195271</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>EC1M 6BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>W1G 8HU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Northwood</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sidcup</city>
        <zip>DA14 6LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4150&amp;filename=PT003014%20Statistical%20Analysis%20Plan%2011_01_01%20_Redacted%20updated%2020181003%20PDFA.pdf</url>
    <description>Updated cover page</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4150&amp;filename=PT003014-05-%20CLINICAL%20STUDY%20PROTOCOL%20Redacted_updated%2020181003%20PDFA.pdf</url>
    <description>Updated Cover page</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4150&amp;filename=PT003014-05-%20CLINICAL%20STUDY%20PROTOCOL%20Redacted%20PDFA.pdf</url>
    <description>Updated Cover page</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4150&amp;filename=PT003014%20Statistical%20Analysis%20Plan%20PDFA.pdf</url>
    <description>Updated cover page</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 6, 2015</study_first_submitted>
  <study_first_submitted_qc>January 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2015</study_first_posted>
  <results_first_submitted>July 11, 2018</results_first_submitted>
  <results_first_submitted_qc>January 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 20, 2019</results_first_posted>
  <last_update_submitted>January 28, 2019</last_update_submitted>
  <last_update_submitted_qc>January 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AstraZeneca's policy is to share data with researchers if the request is in scope of our policy. The policy and additional information can be found on astrazenecaclinicaltrials.com.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT02343458/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT02343458/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 175 sites in the United States, United Kingdom, Taiwan (TW),South Korea (SK), Russia, Poland, Hungary, Germany, Czech Republic, China, and Japan from April 2015 to August 2017. The entire study period was scheduled to take approximately 30 weeks for each individual subject from the time of screening.</recruitment_details>
      <pre_assignment_details>Subjects were randomized in a 7:6:6:3 scheme (GFF MDI, FF MDI, GP MDI, and Placebo MDI). Randomization was stratified by reversibility to Ventolin HFA and COPD disease severity (moderate vs severe or very severe) to ensure a similar distribution of treatment arms across stratum.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GFF MDI 14.4/9.6 ug</title>
          <description>Glycopyrronium, Formoterol Fumarate, Metered Dose Inhalation 14.4/9.6 ug</description>
        </group>
        <group group_id="P2">
          <title>FF MDI 9.6 ug</title>
          <description>Formoterol Fumarate, Metered Dose Inhalation 9.6 ug</description>
        </group>
        <group group_id="P3">
          <title>GP MDI 14.4 ug</title>
          <description>Glycopyrronium 14.4 ug Metered Dose Inhalation</description>
        </group>
        <group group_id="P4">
          <title>Placebo MDI</title>
          <description>Placebo Metered Dose Inhalation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="555"/>
                <participants group_id="P2" count="483"/>
                <participants group_id="P3" count="480"/>
                <participants group_id="P4" count="238"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="494"/>
                <participants group_id="P2" count="417"/>
                <participants group_id="P3" count="417"/>
                <participants group_id="P4" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="38"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Specified Criteria</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The data reported from one site was not included in the final analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>GFF MDI 14.4/9.6 ug</title>
          <description>Glycopyrronium, Formoterol Fumarate, Metered Dose Inhalation 14.4/9.6 ug</description>
        </group>
        <group group_id="B2">
          <title>FF MDI 9.6 ug</title>
          <description>Formoterol Fumarate, Metered Dose Inhalation 9.6 ug</description>
        </group>
        <group group_id="B3">
          <title>GP MDI 14.4 ug</title>
          <description>Glycopyrronium 14.4 ug Metered Dose Inhalation</description>
        </group>
        <group group_id="B4">
          <title>Placebo MDI</title>
          <description>Placebo Metered Dose Inhalation</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="551"/>
            <count group_id="B2" value="480"/>
            <count group_id="B3" value="474"/>
            <count group_id="B4" value="235"/>
            <count group_id="B5" value="1740"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>ITT Population</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.7" spread="7.4"/>
                    <measurement group_id="B2" value="64.1" spread="7.6"/>
                    <measurement group_id="B3" value="64.0" spread="8.1"/>
                    <measurement group_id="B4" value="63.9" spread="7.5"/>
                    <measurement group_id="B5" value="64.2" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>The data reported from one site was not included in the final analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="128"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="450"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="408"/>
                    <measurement group_id="B2" value="365"/>
                    <measurement group_id="B3" value="346"/>
                    <measurement group_id="B4" value="171"/>
                    <measurement group_id="B5" value="1290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="223"/>
                    <measurement group_id="B2" value="204"/>
                    <measurement group_id="B3" value="181"/>
                    <measurement group_id="B4" value="92"/>
                    <measurement group_id="B5" value="700"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="315"/>
                    <measurement group_id="B2" value="260"/>
                    <measurement group_id="B3" value="275"/>
                    <measurement group_id="B4" value="137"/>
                    <measurement group_id="B5" value="987"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 of Treatment (US/China Approach)</title>
        <description>For the US/China approach, the primary endpoint was the change from baseline in morning pre-dose trough FEV1 at Week 24 of treatment</description>
        <time_frame>at week 24</time_frame>
        <population>ITT Population - defined as all subjects who were randomized to treatment and received at least 1 dose of the study treatment. Subjects were analyzed according to the treatment they were assigned to at randomization. Number of participants analyzed reflects the ITT population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 14.4/9.6 ug</title>
            <description>Glycopyrronium, Formoterol Fumarate, Metered Dose Inhalation 14.4/9.6 ug</description>
          </group>
          <group group_id="O2">
            <title>FF MDI 9.6 ug</title>
            <description>Formoterol Fumarate, Metered Dose Inhalation 9.6 ug</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 14.4 ug</title>
            <description>Glycopyrronium 14.4 ug Metered Dose Inhalation</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Placebo Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 of Treatment (US/China Approach)</title>
          <description>For the US/China approach, the primary endpoint was the change from baseline in morning pre-dose trough FEV1 at Week 24 of treatment</description>
          <population>ITT Population - defined as all subjects who were randomized to treatment and received at least 1 dose of the study treatment. Subjects were analyzed according to the treatment they were assigned to at randomization. Number of participants analyzed reflects the ITT population with available data</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="488"/>
                <count group_id="O2" value="413"/>
                <count group_id="O3" value="412"/>
                <count group_id="O4" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" lower_limit="102" upper_limit="138"/>
                    <measurement group_id="O2" value="47" lower_limit="28" upper_limit="67"/>
                    <measurement group_id="O3" value="60" lower_limit="41" upper_limit="80"/>
                    <measurement group_id="O4" value="-45" lower_limit="-73" upper_limit="-17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Morning Pre-dose Trough FEV1 Over Weeks 12-24, Japan Approach</title>
        <description>Change from baseline in morning pre-dose trough FEV1 over weeks 12-24, Japan approach</description>
        <time_frame>over weeks 12-24</time_frame>
        <population>ITT Population - defined as all subjects who were randomized to treatment and received at least 1 dose of the study treatment. Subjects were analyzed according to the treatment they were assigned to at randomization. Number of participants analyzed reflects the ITT population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 14.4/9.6 ug</title>
            <description>Glycopyrronium, Formoterol Fumarate, Metered Dose Inhalation 14.4/9.6 ug</description>
          </group>
          <group group_id="O2">
            <title>FF MDI 9.6 ug</title>
            <description>Formoterol Fumarate, Metered Dose Inhalation 9.6 ug</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 14.4 ug</title>
            <description>Glycopyrronium 14.4 ug Metered Dose Inhalation</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Placebo Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Pre-dose Trough FEV1 Over Weeks 12-24, Japan Approach</title>
          <description>Change from baseline in morning pre-dose trough FEV1 over weeks 12-24, Japan approach</description>
          <population>ITT Population - defined as all subjects who were randomized to treatment and received at least 1 dose of the study treatment. Subjects were analyzed according to the treatment they were assigned to at randomization. Number of participants analyzed reflects the ITT population with available data</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="517"/>
                <count group_id="O2" value="436"/>
                <count group_id="O3" value="437"/>
                <count group_id="O4" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" lower_limit="113" upper_limit="143"/>
                    <measurement group_id="O2" value="54" lower_limit="38" upper_limit="71"/>
                    <measurement group_id="O3" value="74" lower_limit="58" upper_limit="91"/>
                    <measurement group_id="O4" value="-25" lower_limit="-49" upper_limit="-1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks. Primary Endpoint, EU/SK/TW Approach, Secondary Endpoint US/China Approach.</title>
        <description>Change from baseline in morning pre-dose trough FEV1 over 24 weeks. Primary endpoint, EU/SK/TW approach, Secondary endpoint US/China approach.</description>
        <time_frame>over 24 weeks</time_frame>
        <population>ITT Population - defined as all subjects who were randomized to treatment and received at least 1 dose of the study treatment. Subjects were analyzed according to the treatment they were assigned to at randomization. Number of participants analyzed reflects the ITT population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 14.4/9.6 ug</title>
            <description>Glycopyrronium, Formoterol Fumarate, Metered Dose Inhalation 14.4/9.6 ug</description>
          </group>
          <group group_id="O2">
            <title>FF MDI 9.6 ug</title>
            <description>Formoterol Fumarate, Metered Dose Inhalation 9.6 ug</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 14.4 ug</title>
            <description>Glycopyrronium 14.4 ug Metered Dose Inhalation</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Placebo Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks. Primary Endpoint, EU/SK/TW Approach, Secondary Endpoint US/China Approach.</title>
          <description>Change from baseline in morning pre-dose trough FEV1 over 24 weeks. Primary endpoint, EU/SK/TW approach, Secondary endpoint US/China approach.</description>
          <population>ITT Population - defined as all subjects who were randomized to treatment and received at least 1 dose of the study treatment. Subjects were analyzed according to the treatment they were assigned to at randomization. Number of participants analyzed reflects the ITT population with available data</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="541"/>
                <count group_id="O2" value="467"/>
                <count group_id="O3" value="465"/>
                <count group_id="O4" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135" lower_limit="121" upper_limit="149"/>
                    <measurement group_id="O2" value="63" lower_limit="48" upper_limit="78"/>
                    <measurement group_id="O3" value="80" lower_limit="65" upper_limit="94"/>
                    <measurement group_id="O4" value="-20" lower_limit="-41" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TDI Focal Score Over 24 Weeks, US/China and EU/SK/TW Approach</title>
        <description>TDI focal score over 24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9</description>
        <time_frame>over 24 Weeks</time_frame>
        <population>ITT Population - defined as all subjects who were randomized to treatment and received at least 1 dose of the study treatment. Subjects were analyzed according to the treatment they were assigned to at randomization. Number of participants analyzed reflects the ITT population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 14.4/9.6 ug</title>
            <description>Glycopyrronium, Formoterol Fumarate, Metered Dose Inhalation 14.4/9.6 ug</description>
          </group>
          <group group_id="O2">
            <title>FF MDI 9.6 ug</title>
            <description>Formoterol Fumarate, Metered Dose Inhalation 9.6 ug</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 14.4 ug</title>
            <description>Glycopyrronium 14.4 ug Metered Dose Inhalation</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Placebo Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>TDI Focal Score Over 24 Weeks, US/China and EU/SK/TW Approach</title>
          <description>TDI focal score over 24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9</description>
          <population>ITT Population - defined as all subjects who were randomized to treatment and received at least 1 dose of the study treatment. Subjects were analyzed according to the treatment they were assigned to at randomization. Number of participants analyzed reflects the ITT population with available data</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="532"/>
                <count group_id="O2" value="458"/>
                <count group_id="O3" value="457"/>
                <count group_id="O4" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.4" upper_limit="1.8"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.3" upper_limit="1.7"/>
                    <measurement group_id="O3" value="1.3" lower_limit="1.1" upper_limit="1.5"/>
                    <measurement group_id="O4" value="0.8" lower_limit="0.5" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TDI Focal Score Over Weeks 12-24 Japan Approach</title>
        <description>TDI focal score over 12-24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9</description>
        <time_frame>over Weeks 12-24</time_frame>
        <population>ITT Population - defined as all subjects who were randomized to treatment and received at least 1 dose of the study treatment. Subjects were analyzed according to the treatment they were assigned to at randomization. Number of participants analyzed reflects the ITT population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 14.4/9.6 ug</title>
            <description>Glycopyrronium, Formoterol Fumarate, Metered Dose Inhalation 14.4/9.6 ug</description>
          </group>
          <group group_id="O2">
            <title>FF MDI 9.6 ug</title>
            <description>Formoterol Fumarate, Metered Dose Inhalation 9.6 ug</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 14.4 ug</title>
            <description>Glycopyrronium 14.4 ug Metered Dose Inhalation</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Placebo Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>TDI Focal Score Over Weeks 12-24 Japan Approach</title>
          <description>TDI focal score over 12-24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9</description>
          <population>ITT Population - defined as all subjects who were randomized to treatment and received at least 1 dose of the study treatment. Subjects were analyzed according to the treatment they were assigned to at randomization. Number of participants analyzed reflects the ITT population with available data</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="515"/>
                <count group_id="O2" value="434"/>
                <count group_id="O3" value="436"/>
                <count group_id="O4" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.5" upper_limit="1.9"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.3" upper_limit="1.7"/>
                    <measurement group_id="O3" value="1.4" lower_limit="1.2" upper_limit="1.6"/>
                    <measurement group_id="O4" value="0.8" lower_limit="0.5" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TDI Focal Score Over 24 Weeks - US/China and EU/SK/TW Approaches -Symptomatic Population</title>
        <description>TDI focal score over 24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9</description>
        <time_frame>over 24 Weeks</time_frame>
        <population>Symptomatic Population was defined as all subjects in the ITT Population with CAT scores of ≥15 at Visit 2</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 14.4/9.6 ug</title>
            <description>Glycopyrronium, Formoterol Fumarate, Metered Dose Inhalation 14.4/9.6 ug</description>
          </group>
          <group group_id="O2">
            <title>FF MDI 9.6 ug</title>
            <description>Formoterol Fumarate, Metered Dose Inhalation 9.6 ug</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 14.4 ug</title>
            <description>Glycopyrronium 14.4 ug Metered Dose Inhalation</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Placebo Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>TDI Focal Score Over 24 Weeks - US/China and EU/SK/TW Approaches -Symptomatic Population</title>
          <description>TDI focal score over 24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9</description>
          <population>Symptomatic Population was defined as all subjects in the ITT Population with CAT scores of ≥15 at Visit 2</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="217"/>
                <count group_id="O3" value="228"/>
                <count group_id="O4" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.2" upper_limit="1.7"/>
                    <measurement group_id="O2" value="1.3" lower_limit="1.0" upper_limit="1.6"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.8" upper_limit="1.3"/>
                    <measurement group_id="O4" value="0.7" lower_limit="0.3" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TDI Focal Score Over Weeks 12-24 - Japan Approach - Symptomatic Population</title>
        <description>TDI focal score over 12-24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9</description>
        <time_frame>over weeks 12-24</time_frame>
        <population>Symptomatic Population was defined as all subjects in the ITT Population with CAT scores of ≥15 at Visit 2</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 14.4/9.6 ug</title>
            <description>Glycopyrronium, Formoterol Fumarate, Metered Dose Inhalation 14.4/9.6 ug</description>
          </group>
          <group group_id="O2">
            <title>FF MDI 9.6 ug</title>
            <description>Formoterol Fumarate, Metered Dose Inhalation 9.6 ug</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 14.4 ug</title>
            <description>Glycopyrronium 14.4 ug Metered Dose Inhalation</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Placebo Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>TDI Focal Score Over Weeks 12-24 - Japan Approach - Symptomatic Population</title>
          <description>TDI focal score over 12-24 Weeks as a Model-Based Average (ITT Population) The TDI is an instrument which measures the changes in the participant's dyspnea from Baseline. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9</description>
          <population>Symptomatic Population was defined as all subjects in the ITT Population with CAT scores of ≥15 at Visit 2</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="218"/>
                <count group_id="O4" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="1.2" upper_limit="1.8"/>
                    <measurement group_id="O2" value="1.4" lower_limit="1.0" upper_limit="1.7"/>
                    <measurement group_id="O3" value="1.1" lower_limit="0.8" upper_limit="1.4"/>
                    <measurement group_id="O4" value="0.7" lower_limit="0.2" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing at Week 24 US/China Approach</title>
        <description>Peak change from baseline in FEV1 within 2 hours post-dosing at Week 24 US/China approach</description>
        <time_frame>at week 24</time_frame>
        <population>ITT Population - defined as all subjects who were randomized to treatment and received at least 1 dose of the study treatment. Subjects were analyzed according to the treatment they were assigned to at randomization. Number of participants analyzed reflects the ITT population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 14.4/9.6 ug</title>
            <description>Glycopyrronium, Formoterol Fumarate, Metered Dose Inhalation 14.4/9.6 ug</description>
          </group>
          <group group_id="O2">
            <title>FF MDI 9.6 ug</title>
            <description>Formoterol Fumarate, Metered Dose Inhalation 9.6 ug</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 14.4 ug</title>
            <description>Glycopyrronium 14.4 ug Metered Dose Inhalation</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Placebo Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing at Week 24 US/China Approach</title>
          <description>Peak change from baseline in FEV1 within 2 hours post-dosing at Week 24 US/China approach</description>
          <population>ITT Population - defined as all subjects who were randomized to treatment and received at least 1 dose of the study treatment. Subjects were analyzed according to the treatment they were assigned to at randomization. Number of participants analyzed reflects the ITT population with available data</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="490"/>
                <count group_id="O2" value="413"/>
                <count group_id="O3" value="412"/>
                <count group_id="O4" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="358" lower_limit="338" upper_limit="378"/>
                    <measurement group_id="O2" value="247" lower_limit="226" upper_limit="269"/>
                    <measurement group_id="O3" value="214" lower_limit="192" upper_limit="235"/>
                    <measurement group_id="O4" value="55" lower_limit="24" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over Weeks 12-24 Japan Approach</title>
        <description>Peak change from baseline in FEV1 within 2 hours post-dosing over weeks 12-24 Japan approach</description>
        <time_frame>over weeks 12-24</time_frame>
        <population>ITT Population - defined as all subjects who were randomized to treatment and received at least 1 dose of the study treatment. Subjects were analyzed according to the treatment they were assigned to at randomization. Number of participants analyzed reflects the ITT population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 14.4/9.6 ug</title>
            <description>Glycopyrronium, Formoterol Fumarate, Metered Dose Inhalation 14.4/9.6 ug</description>
          </group>
          <group group_id="O2">
            <title>FF MDI 9.6 ug</title>
            <description>Formoterol Fumarate, Metered Dose Inhalation 9.6 ug</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 14.4 ug</title>
            <description>Glycopyrronium 14.4 ug Metered Dose Inhalation</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Placebo Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over Weeks 12-24 Japan Approach</title>
          <description>Peak change from baseline in FEV1 within 2 hours post-dosing over weeks 12-24 Japan approach</description>
          <population>ITT Population - defined as all subjects who were randomized to treatment and received at least 1 dose of the study treatment. Subjects were analyzed according to the treatment they were assigned to at randomization. Number of participants analyzed reflects the ITT population with available data</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="516"/>
                <count group_id="O2" value="436"/>
                <count group_id="O3" value="436"/>
                <count group_id="O4" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="368" lower_limit="350" upper_limit="386"/>
                    <measurement group_id="O2" value="255" lower_limit="236" upper_limit="274"/>
                    <measurement group_id="O3" value="228" lower_limit="209" upper_limit="248"/>
                    <measurement group_id="O4" value="70" lower_limit="42" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over 24 Weeks EU/SK/TW Approach</title>
        <description>Peak change from baseline in FEV1 within 2 hours post-dosing over 24 weeks EU/SK/TW approach</description>
        <time_frame>over 24 weeks</time_frame>
        <population>ITT Population - defined as all subjects who were randomized to treatment and received at least 1 dose of the study treatment. Subjects were analyzed according to the treatment they were assigned to at randomization. Number of participants analyzed reflects the ITT population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 14.4/9.6 ug</title>
            <description>Glycopyrronium, Formoterol Fumarate, Metered Dose Inhalation 14.4/9.6 ug</description>
          </group>
          <group group_id="O2">
            <title>FF MDI 9.6 ug</title>
            <description>Formoterol Fumarate, Metered Dose Inhalation 9.6 ug</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 14.4 ug</title>
            <description>Glycopyrronium 14.4 ug Metered Dose Inhalation</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Placebo Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in FEV1 Within 2 Hours Post-dosing Over 24 Weeks EU/SK/TW Approach</title>
          <description>Peak change from baseline in FEV1 within 2 hours post-dosing over 24 weeks EU/SK/TW approach</description>
          <population>ITT Population - defined as all subjects who were randomized to treatment and received at least 1 dose of the study treatment. Subjects were analyzed according to the treatment they were assigned to at randomization. Number of participants analyzed reflects the ITT population with available data</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="550"/>
                <count group_id="O2" value="480"/>
                <count group_id="O3" value="474"/>
                <count group_id="O4" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="375" lower_limit="360" upper_limit="389"/>
                    <measurement group_id="O2" value="277" lower_limit="261" upper_limit="293"/>
                    <measurement group_id="O3" value="234" lower_limit="218" upper_limit="250"/>
                    <measurement group_id="O4" value="82" lower_limit="58" upper_limit="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SGRQ Total Score at Week 24, US/China Approach</title>
        <description>Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life</description>
        <time_frame>at week 24</time_frame>
        <population>ITT Population - defined as all subjects who were randomized to treatment and received at least 1 dose of the study treatment. Subjects were analyzed according to the treatment they were assigned to at randomization. Number of participants analyzed reflects the ITT population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 14.4/9.6 ug</title>
            <description>Glycopyrronium, Formoterol Fumarate, Metered Dose Inhalation 14.4/9.6 ug</description>
          </group>
          <group group_id="O2">
            <title>FF MDI 9.6 ug</title>
            <description>Formoterol Fumarate, Metered Dose Inhalation 9.6 ug</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 14.4 ug</title>
            <description>Glycopyrronium 14.4 ug Metered Dose Inhalation</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Placebo Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SGRQ Total Score at Week 24, US/China Approach</title>
          <description>Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life</description>
          <population>ITT Population - defined as all subjects who were randomized to treatment and received at least 1 dose of the study treatment. Subjects were analyzed according to the treatment they were assigned to at randomization. Number of participants analyzed reflects the ITT population with available data</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="489"/>
                <count group_id="O2" value="415"/>
                <count group_id="O3" value="412"/>
                <count group_id="O4" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" lower_limit="-6.4" upper_limit="-4.2"/>
                    <measurement group_id="O2" value="-5.6" lower_limit="-6.8" upper_limit="-4.4"/>
                    <measurement group_id="O3" value="-3.7" lower_limit="-4.8" upper_limit="-2.5"/>
                    <measurement group_id="O4" value="-0.9" lower_limit="-2.6" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SGRQ Total Score Over Weeks 12-24 , Japan &amp; EU/SK/TW Approach</title>
        <description>Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life</description>
        <time_frame>over weeks 12-24</time_frame>
        <population>ITT Population - defined as all subjects who were randomized to treatment and received at least 1 dose of the study treatment. Subjects were analyzed according to the treatment they were assigned to at randomization. Number of participants analyzed reflects the ITT population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 14.4/9.6 ug</title>
            <description>Glycopyrronium, Formoterol Fumarate, Metered Dose Inhalation 14.4/9.6 ug</description>
          </group>
          <group group_id="O2">
            <title>FF MDI 9.6 ug</title>
            <description>Formoterol Fumarate, Metered Dose Inhalation 9.6 ug</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 14.4 ug</title>
            <description>Glycopyrronium 14.4 ug Metered Dose Inhalation</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Placebo Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SGRQ Total Score Over Weeks 12-24 , Japan &amp; EU/SK/TW Approach</title>
          <description>Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life</description>
          <population>ITT Population - defined as all subjects who were randomized to treatment and received at least 1 dose of the study treatment. Subjects were analyzed according to the treatment they were assigned to at randomization. Number of participants analyzed reflects the ITT population with available data</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="516"/>
                <count group_id="O2" value="436"/>
                <count group_id="O3" value="436"/>
                <count group_id="O4" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" lower_limit="-6.1" upper_limit="-4.3"/>
                    <measurement group_id="O2" value="-5.0" lower_limit="-5.9" upper_limit="-4.0"/>
                    <measurement group_id="O3" value="-3.6" lower_limit="-4.6" upper_limit="-2.6"/>
                    <measurement group_id="O4" value="-1.7" lower_limit="-3.1" upper_limit="-0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SGRQ Total Score at Week 24 in Symptomatic Population, US/China Approach</title>
        <description>Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life</description>
        <time_frame>at week 24</time_frame>
        <population>Symptomatic Population was defined as all subjects in the ITT Population with CAT scores of ≥15 at Visit 2n</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 14.4/9.6 ug</title>
            <description>Glycopyrronium, Formoterol Fumarate, Metered Dose Inhalation 14.4/9.6 ug</description>
          </group>
          <group group_id="O2">
            <title>FF MDI 9.6 ug</title>
            <description>Formoterol Fumarate, Metered Dose Inhalation 9.6 ug</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 14.4 ug</title>
            <description>Glycopyrronium 14.4 ug Metered Dose Inhalation</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Placebo Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SGRQ Total Score at Week 24 in Symptomatic Population, US/China Approach</title>
          <description>Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life</description>
          <population>Symptomatic Population was defined as all subjects in the ITT Population with CAT scores of ≥15 at Visit 2n</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="189"/>
                <count group_id="O3" value="202"/>
                <count group_id="O4" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.9" lower_limit="-8.6" upper_limit="-5.2"/>
                    <measurement group_id="O2" value="-7.8" lower_limit="-9.7" upper_limit="-5.9"/>
                    <measurement group_id="O3" value="-3.8" lower_limit="-5.6" upper_limit="-2.0"/>
                    <measurement group_id="O4" value="-1.6" lower_limit="-4.3" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SGRQ Total Score Over Weeks 12-24, in Symptomatic Population, Japan &amp; EU/SK/TW Approach</title>
        <description>Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life</description>
        <time_frame>over weeks 12-24</time_frame>
        <population>Symptomatic Population was defined as all subjects in the ITT Population with CAT scores of ≥15 at Visit 2</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 14.4/9.6 ug</title>
            <description>Glycopyrronium, Formoterol Fumarate, Metered Dose Inhalation 14.4/9.6 ug</description>
          </group>
          <group group_id="O2">
            <title>FF MDI 9.6 ug</title>
            <description>Formoterol Fumarate, Metered Dose Inhalation 9.6 ug</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 14.4 ug</title>
            <description>Glycopyrronium 14.4 ug Metered Dose Inhalation</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Placebo Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SGRQ Total Score Over Weeks 12-24, in Symptomatic Population, Japan &amp; EU/SK/TW Approach</title>
          <description>Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life</description>
          <population>Symptomatic Population was defined as all subjects in the ITT Population with CAT scores of ≥15 at Visit 2</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="218"/>
                <count group_id="O4" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.9" lower_limit="-8.4" upper_limit="-5.4"/>
                    <measurement group_id="O2" value="-7.3" lower_limit="-8.9" upper_limit="-5.6"/>
                    <measurement group_id="O3" value="-3.9" lower_limit="-5.5" upper_limit="-2.4"/>
                    <measurement group_id="O4" value="-3.1" lower_limit="-5.4" upper_limit="-0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Daily Rescue Ventolin Use Over 24 Weeks in RVU Population, All Approaches</title>
        <description>Change from baseline in average daily rescue Ventolin use over 24 weeks in RVU population, all approaches</description>
        <time_frame>over 24 weeks</time_frame>
        <population>RVU Population - defined as Rescue Ventolin User</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 14.4/9.6 ug</title>
            <description>Glycopyrronium, Formoterol Fumarate, Metered Dose Inhalation 14.4/9.6 ug</description>
          </group>
          <group group_id="O2">
            <title>FF MDI 9.6 ug</title>
            <description>Formoterol Fumarate, Metered Dose Inhalation 9.6 ug</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 14.4 ug</title>
            <description>Glycopyrronium 14.4 ug Metered Dose Inhalation</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Placebo Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Daily Rescue Ventolin Use Over 24 Weeks in RVU Population, All Approaches</title>
          <description>Change from baseline in average daily rescue Ventolin use over 24 weeks in RVU population, all approaches</description>
          <population>RVU Population - defined as Rescue Ventolin User</population>
          <units>Puffs/day</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="256"/>
                <count group_id="O2" value="232"/>
                <count group_id="O3" value="225"/>
                <count group_id="O4" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" lower_limit="-1.7" upper_limit="-1.1"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-1.3" upper_limit="-0.7"/>
                    <measurement group_id="O3" value="-0.6" lower_limit="-0.9" upper_limit="-0.3"/>
                    <measurement group_id="O4" value="-0.4" lower_limit="-0.8" upper_limit="-0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Measured at 5 Minutes Post-dose on Day 1</title>
        <description>Onset of Action as Assessed by FEV1 Day 1 at 5 Minutes Post-Dose. Reported is the FEV1 measured at 5 minutes post-dose on Day 1 as the first time point when the difference from Placebo was statistically significant</description>
        <time_frame>Assessed at 5-minutes post dose on Day 1</time_frame>
        <population>ITT Population - defined as all subjects who were randomized to treatment and received at least 1 dose of the study treatment. Subjects were analyzed according to the treatment they were assigned to at randomization. Number of participants analyzed reflects the ITT population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 14.4/9.6 ug</title>
            <description>Glycopyrronium, Formoterol Fumarate, Metered Dose Inhalation 14.4/9.6 ug</description>
          </group>
          <group group_id="O2">
            <title>FF MDI 9.6 ug</title>
            <description>Formoterol Fumarate, Metered Dose Inhalation 9.6 ug</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 14.4 ug</title>
            <description>Glycopyrronium 14.4 ug Metered Dose Inhalation</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Placebo Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Measured at 5 Minutes Post-dose on Day 1</title>
          <description>Onset of Action as Assessed by FEV1 Day 1 at 5 Minutes Post-Dose. Reported is the FEV1 measured at 5 minutes post-dose on Day 1 as the first time point when the difference from Placebo was statistically significant</description>
          <population>ITT Population - defined as all subjects who were randomized to treatment and received at least 1 dose of the study treatment. Subjects were analyzed according to the treatment they were assigned to at randomization. Number of participants analyzed reflects the ITT population with available data</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="464"/>
                <count group_id="O2" value="406"/>
                <count group_id="O3" value="403"/>
                <count group_id="O4" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.202" lower_limit="0.191" upper_limit="0.212"/>
                    <measurement group_id="O2" value="0.186" lower_limit="0.175" upper_limit="0.197"/>
                    <measurement group_id="O3" value="0.059" lower_limit="0.048" upper_limit="0.070"/>
                    <measurement group_id="O4" value="0.022" lower_limit="0.006" upper_limit="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Measured at 15 Minutes Post-dose on Day 1</title>
        <description>Onset of Action as Assessed by FEV1 Day 1 at 15 Minutes Post-Dose. Reported is the FEV1 measured at 15 minutes post-dose on Day 1 as the first time point when the difference from Placebo was statistically significant</description>
        <time_frame>Assessed at 15-minute post dose on Day 1</time_frame>
        <population>ITT Population - defined as all subjects who were randomized to treatment and received at least 1 dose of the study treatment. Subjects were analyzed according to the treatment they were assigned to at randomization. Number of participants analyzed reflects the ITT population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 14.4/9.6 ug</title>
            <description>Glycopyrronium, Formoterol Fumarate, Metered Dose Inhalation 14.4/9.6 ug</description>
          </group>
          <group group_id="O2">
            <title>FF MDI 9.6 ug</title>
            <description>Formoterol Fumarate, Metered Dose Inhalation 9.6 ug</description>
          </group>
          <group group_id="O3">
            <title>GP MDI 14.4 ug</title>
            <description>Glycopyrronium 14.4 ug Metered Dose Inhalation</description>
          </group>
          <group group_id="O4">
            <title>Placebo MDI</title>
            <description>Placebo Metered Dose Inhalation</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Measured at 15 Minutes Post-dose on Day 1</title>
          <description>Onset of Action as Assessed by FEV1 Day 1 at 15 Minutes Post-Dose. Reported is the FEV1 measured at 15 minutes post-dose on Day 1 as the first time point when the difference from Placebo was statistically significant</description>
          <population>ITT Population - defined as all subjects who were randomized to treatment and received at least 1 dose of the study treatment. Subjects were analyzed according to the treatment they were assigned to at randomization. Number of participants analyzed reflects the ITT population with available data</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="530"/>
                <count group_id="O2" value="458"/>
                <count group_id="O3" value="453"/>
                <count group_id="O4" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.241" lower_limit="0.230" upper_limit="0.252"/>
                    <measurement group_id="O2" value="0.220" lower_limit="0.208" upper_limit="0.231"/>
                    <measurement group_id="O3" value="0.105" lower_limit="0.093" upper_limit="0.117"/>
                    <measurement group_id="O4" value="0.033" lower_limit="0.016" upper_limit="0.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time the subject signed consent throughout the four treatment periods of 24 weeks and up to 10 days following the last dose of study drug.</time_frame>
      <desc>The Safety Population was defined as all subjects who were randomized to treatment regardless and received at least one dose of study treatment. Serious adverse events collected from the time the subject signed consent up to 14 days following the last dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>GFF MDI 14.4/9.6 ug</title>
          <description>Glycopyrronium, Formoterol Fumarate, Metered Dose Inhalation 14.4/9.6 ug</description>
        </group>
        <group group_id="E2">
          <title>FF MDI 9.6 ug</title>
          <description>Formoterol Fumarate, Metered Dose Inhalation 9.6 ug</description>
        </group>
        <group group_id="E3">
          <title>GP MDI 14.4 ug</title>
          <description>Glycopyrronium 14.4 ug Metered Dose Inhalation</description>
        </group>
        <group group_id="E4">
          <title>Placebo MDI</title>
          <description>Placebo Metered Dose Inhalation</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="480"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="474"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Angel closure glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Colitis ischemic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Haemorroids thrombosed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="551"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="474"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="480"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Borrelia Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Humerous fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes melitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Spondyloarthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Breast neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Cardiac myxoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Haemangiopericytoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Hypoglycemic coma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pseudoradicular syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Somatic symptom disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="551"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="480"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="474"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Asthma-chronic obstructive pulmonary disease overlap syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="480"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="166" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="123" subjects_at_risk="480"/>
                <counts group_id="E3" subjects_affected="128" subjects_at_risk="474"/>
                <counts group_id="E4" subjects_affected="61" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="56" subjects_affected="50" subjects_at_risk="551"/>
                <counts group_id="E2" events="52" subjects_affected="46" subjects_at_risk="480"/>
                <counts group_id="E3" events="55" subjects_affected="44" subjects_at_risk="474"/>
                <counts group_id="E4" events="17" subjects_affected="16" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="44" subjects_affected="37" subjects_at_risk="551"/>
                <counts group_id="E2" events="34" subjects_affected="29" subjects_at_risk="480"/>
                <counts group_id="E3" events="40" subjects_affected="33" subjects_at_risk="474"/>
                <counts group_id="E4" events="24" subjects_affected="20" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="551"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="480"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="474"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="551"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="480"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="474"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="551"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="480"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="474"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="551"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="480"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="474"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="551"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="480"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="474"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="551"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="480"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="474"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="235"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="551"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="480"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="474"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="235"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent it's opinions, or the opinions of the publication committee, if these differ with the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pearl Therapeutics Inc.</name_or_title>
      <organization>Pearl Therapeutics Inc.</organization>
      <phone>650-305-2600</phone>
      <email>creisner@pearltherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

